Alcobra Ltd is a biopharmaceutical company. It is focused on the development and commercialization of novel treatments for central nervous system and cognitive disorders. The company' s product candidates include Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy; and Metadoxine Extended Release (MDX), a proprietary oral drug for the treatment of ADHD and other cognitive disorders, including Fragile X syndrome. Geographically all the operations are operated through the regions of Israel.